Skip to main
ENLV
ENLV logo

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd is strategically enhancing its liquidity through an at-the-market (ATM) program, enabling the company to capitalize on elevated trading volumes to fund the development of its promising drug pipeline, particularly Allocetra. The recent Phase IIa trial results for Allocetra have shown statistically significant and clinically meaningful improvements in pain and functional outcomes for patients, especially those aged 60 and older suffering from idiopathic age-related osteoarthritis, a large market segment. Additionally, the company's proactive efforts in securing intellectual property, such as a new patent application related to Allocetra, further solidify its competitive edge and potential for future growth in the biopharmaceutical space.

Bears say

Enlivex Therapeutics is currently facing challenges related to its strategic pivot, necessitating additional time for the market and investors to grasp its implications, which has prompted a reassessment of stock outlook. The company appears to be grappling with a disconnect between its clinical progress and market recognition, leading management to pursue unconventional capital access methods, including a digital asset strategy that may not resonate with traditional investors. Furthermore, while there are potential milestones in their KOA program that could de-risk the future, uncertainties surrounding ongoing trials and capital strategies contribute to a negative financial outlook.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.